Prostate adenocarcinoma: a new integrated diagnostic approach aimed at the therapeutic choice
https://doi.org/10.4081/wpph.2016.6695
Submitted: 11 July 2016
Accepted: 11 July 2016
Published: 15 June 2016
Accepted: 11 July 2016
Abstract Views: 712
PDF: 2528
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Prostate cancer is different in clinical presentation, histopathological tumor growth, patterns and survival than others cancer. Therefore, individual assessment of a tumor’s aggressive potential is crucial for clinical decision-making in men with prostate cancer. Here we discuss the potential role of ERG and CD117 as a prognostic factors and molecular targets in needle biopsy on prostate cancer.
Delle Fave, A., & Erra, S. (2016). Prostate adenocarcinoma: a new integrated diagnostic approach aimed at the therapeutic choice. Working Paper of Public Health, 5(1). https://doi.org/10.4081/wpph.2016.6695
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Download data is not yet available.
Citations
